Elon Musk's brain-to-computer venture Neuralink has its second product on the launchpad, and it's a doozy.
In a post on X, Musk said Blindsight would enable people who are completely blind or have never been able to see to gain sight.
"It is ready from an engineering standpoint," he wrote. "Just waiting on regulatory approval."
Our second product is called Blindsight and it will, as the name suggests, enable even those who are completely blind or have never seen to see. It is ready from an engineering standpoint. Just waiting on regulatory approval.
— Elon Musk (@elonmusk) October 30, 2026
Neuralink was founded in 2016. Its first product, Telepathy, enables high-speed communication with computers or humans simply by thinking, according to Musk.
While much brain-computer interface (BCI) research has focused on people controlling objects with their brain, Blindsight uses a camera to produce visual information.
That information is converted into stimulation instructions and sent to a device implanted in the brain, which interprets the stimulation as visual sensations.
The sensations are perceived as spots or flashes of light called phosphenes. By driving thousands of these points simultaneously, the brain constructs a real-time, low-resolution visual map of a person's surroundings.
The result is synthetic vision, which initially will be coarse and low-resolution, rather than normal eyesight.
Although Blindsight may be ready from an engineering standpoint, it will likely be waiting around for regulatory approval for some time.
"There's a big gap between 'the device works on the bench' and 'the FDA will let you put it in people's brains,'" declared Fylaktis Fylaktou , a postdoctoral researcher at UCLA's Semel Institute for Neuroscience and Human Behavior.
"A cortical visual prosthesis is a Class III device, which is the most heavily regulated category we have," he told TechNewsWorld. "Approval requires staged safety trials over several years."
"Musk's announcement tells you Neuralink has manufacturing confidence in their hardware, but the regulatory timeline is another problem," he said.
"The basic method isn't new," he continued. He pointed out that William H. Dobelle, a biomedical researcher at the University of Utah and pioneer in artificial vision, demonstrated phosphene generation from cortical stimulation back in the 1970s.
"What Neuralink brings is higher electrode density and a surgical robot that makes implantation scalable," he explained. "That's engineering progress, not a scientific breakthrough."
"What patients will actually perceive is ultra-low-resolution patterned light, closer to a dot-matrix display than vision," he said.
"In people who have been blind since birth, the visual cortex has typically been recruited for other functions like touch, hearing, and language," he added. "Stimulating it may not produce visual experience at all."
Daniel Palanker , a professor of ophthalmology at Stanford University's School of Medicine and a researcher of optical and electronic technologies for diagnostic, therapeutic, surgical and prosthetic applications, noted that two studies with cortical stimulation for restoration of sight in human patients demonstrated a major problem with the approach.
"Pattern stimulation does not result in a corresponding patterned perception," he told TechNewsWorld. "Electrodes can elicit perception of flashing light — phosphene — but several electrodes activated in a pattern do not produce…